BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Tolerx, Inc. Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer


8/4/2010 9:16:59 AM

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the appointment of Antonin (Tony) de Fougerolles, Ph.D., as Chief Scientific Officer. Dr. de Fougerolles appointment as Tolerxs CSO will provide leadership for the companys research and early-stage product development programs involving novel therapies based on T cell modulation. Dr. de Fougerolles brings to Tolerx more than 15 years of biotech R&D experience and expertise in immunology. He will direct the companys R&D activities and strengthen Tolerxs leadership in T cell immunology.

(Photo: http://photos.prnewswire.com/prnh/20100804/NE45601 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100804/NE45601 )

"We are delighted and enthusiastic about Tony joining us as CSO at this pivotal time, when Tolerx is poised to make substantial progress in expanding our pipeline of drug candidates based on T cell modulation," said Dr. Douglas J. Ringler, Chief Executive Officer of Tolerx. "Tony brings world-class R&D experience from well-known biotech companies, and his skills and expertise will extend our scientific leadership in T cell modulation and help lead Tolerx through our next stage of growth as we broaden our pipeline of innovative T cell therapies.

Prior to joining Tolerx, Dr. de Fougerolles was Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals. Dr. de Fougerolles joined Alnylam in 2003, holding positions of increasing responsibility and playing a key role in the development of several research programs, including those with Alnylam partners Novartis and Roche. Before joining Alnylam, he served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.), where he had worked since 1998. At Biogen, Dr. de Fougerolles worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. Dr. de Fougerolles earned his Ph.D. in Immunology from Harvard University, and was a Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.

I am very excited to join Tolerx at this time of transformational growth, and believe the depth and quality of Tolerxs team and expertise in T cell modulation position the company to significantly advance and build its pipeline of new therapeutics, said Dr. de Fougerolles. I am particularly enthusiastic about helping to advance the product pipeline and playing a key role in developing novel therapies that are on the cutting edge of exploiting the science of T cell activity to treat autoimmune diseases and cancer in fundamentally new ways."

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The companys pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward humoral immune responses. The company also has three pre-clinical candidates, TRX518, TRX585, and TRX385, that enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerrx.com.

SOURCE Tolerx, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->